BiopharmaTrend.com

Totient

Totient

Private company
TOTIENT
Cambridge, Massachusetts

Totient is an AI-driven biotechnology company leveraging tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. Totient reconstructs antibodies from tissues affected by autoimmunity, infections, and cancer collected from patients experiencing exceptional immune responses. Beginning with a population of over 50,000 samples, we have reconstructed antibodies against known and novel extracellular oncology targets: GAGE1, GAGE2A, ANXA1, C4BPB, IL14A, BIRC7, HCLS1, GPR83, and others undisclosed.


Founded
2017
Status
Private company
Geography
United States of America based
Funding
$10 M

Products

No products posted yet

Services

No services posted yet


This data is part of our proprietary analytics report:

This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality

Go to home page